Product category:
Contract research
News Release from: Ultrafine | Subject: CBT1008
Edited by the Laboratorytalk Editorial
Team on 17 December 2003
Developing neuropathic pain candidate
First phase of chemical process development and scale-up for drug candidate to treat disease of multiple aetiology has been completed
Ultrafine says it has successfully completed the first phase of the chemical process development and scale-up of Cambridge Biotechnology's (CBT) lead compound, CBT1008 Selected to enter non-clinical development for the treatment of neuropathic pain earlier this year, batches of CBT1008 produced by Ultrafine will enable CBT to complete its pre-clinical studies
This article was originally published on Laboratorytalk on 12 Feb 2004 at 8.00am (UK)
Related stories
Phase 1 candidate produced to GMP
Involvement started when the chemistry was initially transferred, through to scale-up and production of pre-clinical material, and subsequent GMP manufacture
The next phase of the project will involve manufacture by Ultrafine of CBT1008 to GMP for use in clinical trials.
Ultrafine was selected to provide a range of chemical development services for CBT1008 in August 2002, initially synthesising small quantities of material to support CBT's short-term requirements.
Subsequently, Ultrafine conducted extensive process development work to establish a scalable route.
Tony Sedgwick, CEO of Cambridge Biotechnology said, "We are delighted with Ultrafine's contributions to the CBT1008 development programme and look forward to continuing our relationship with them into the clinical trial phase"'.
Neuropathic pain is a disease of multiple aetiology, associated with a diverse variety of conditions including diabetic neuropathy, viral infection and back pain.
It is poorly treated by existing medication and has been a major target of pharmaceutical research.
In tests so far CBT1008 has proven to be a significant improvement over existing treatments.
• Ultrafine: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
